在最新电话会议中,Xenon制药高管强调,其核心产品Azetukalner凭借突破性临床数据和全新作用机制,亟需制定与之匹配的优化定价策略。该高管直言,公司早期疗法因定价未能充分体现临床价值而存在"低估"现象。
在最新电话会议中,Xenon制药高管强调,其核心产品Azetukalner凭借突破性临床数据和全新作用机制,亟需制定与之匹配的优化定价策略。该高管直言,公司早期疗法因定价未能充分体现临床价值而存在"低估"现象。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.